Moderate

Alport syndrome

Alport · Renal / Electrolyte
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Hereditary type IV collagen disorder (most commonly X-linked COL4A5) causing progressive haematuric nephritis with sensorineural hearing loss and ocular abnormalities. Early RAAS blockade slows progression toward end-stage kidney disease.

Red flags

  • Rapidly rising proteinuria or declining eGFR
  • Progressive hearing loss
  • Ocular changes (lenticonus, maculopathy)
  • Family history of early kidney failure
  • Post-transplant anti-GBM-like nephritis (rare)

Assessment

Differential diagnosis

  • Thin basement membrane nephropathy
  • IgA nephropathy
  • Other hereditary nephritis
  • Acquired glomerulonephritis
  • Fabry disease
  • Autosomal forms of Alport (COL4A3/COL4A4)

Investigations

  • Urinalysis and urine ACR/PCR (persistent haematuria +/- proteinuria)
  • Renal function trend
  • Audiometry for sensorineural hearing loss
  • Ophthalmology (anterior lenticonus, dot-and-fleck retinopathy)
  • Genetic testing (COL4A3/4/5) — now preferred to biopsy
  • Family history/pedigree; kidney biopsy with electron microscopy if genetics unavailable

Management

  • Suspect in persistent glomerular haematuria with family history of kidney failure and/or hearing loss
  • Confirm with genetic testing of COL4A3/COL4A4/COL4A5 (first-line); reserve biopsy with EM (basket-weave GBM) for uncertain cases
  • Establish inheritance pattern and counsel family; offer cascade screening
  • Quantify proteinuria and monitor eGFR to assess progression risk
  • Start ACE inhibitor (or ARB) early, even with microalbuminuria, to delay progression
  • Optimise blood pressure to a low target
  • Arrange baseline and periodic audiology and ophthalmology review
  • Avoid nephrotoxins and manage cardiovascular risk
  • Discuss SGLT2 inhibitor as adjunct in proteinuric CKD where appropriate
  • Plan for renal replacement/transplant as CKD advances (transplant generally does well; rare anti-GBM-like disease post-transplant)
  • Provide genetic counselling for reproductive decisions
  • Monitor renal function, proteinuria, BP, hearing and eyes at regular intervals

Drugs & doses

Ramipril 2.5-10 mg PO daily (start early even with microalbuminuria)
Losartan 50-100 mg PO daily (if ACEi not tolerated)
Dapagliflozin 10 mg PO once daily (adjunct for proteinuric CKD)
Amlodipine 5-10 mg PO daily (additional BP control)

Disposition

Nephrology clinic with genetics, audiology and ophthalmology input. Family screening. Transplant assessment as CKD advances.

Complications & pitfalls

  • Progressive CKD and end-stage kidney disease
  • Sensorineural deafness
  • Ocular complications and visual impairment
  • Rare post-transplant anti-GBM nephritis
  • Aortic/vascular involvement in some genotypes

Exam pearls

  • Early RAAS blockade (even microalbuminuria) delays kidney failure — the key intervention
  • Genetic testing has largely replaced biopsy for diagnosis
  • Think Alport in haematuria plus deafness or a strong family history
  • Carrier females (X-linked) can still progress and need monitoring
  • Thin basement membrane disease and autosomal Alport overlap genetically

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.